arrow
F

Francisco Mesonero

Hospital Universitario Ramón y Cajal
H指数:20
被引数:3,028

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Characteristics, management, and long-term outcomes of pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease: Data from the ENEIDA registry

炎症性肠病中坏疽性脓皮病和结节性红斑的特征、管理及长期结局:ENEIDA登记研究数据

2026-11-030
PRE
Impact of Prior Biologic Mechanism of Action on Anti‐ TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study

先前生物制剂作用机制对炎症性肠病中抗TNF疗效的影响:一项ENEIDA注册研究

2026-08-120
PREAI
Time trends in strategies for postoperative Crohn’s disease management and long-term surgical recurrence: ENEIDA registry data.

术后克罗恩病管理策略的时间趋势及长期手术复发:ENEIDA注册研究数据

2026-07-150
PRE
Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry

瑞莎珠单抗在难治性克罗恩病中的真实世界有效性:来自ENEIDA登记研究的RISANCROHN研究

2026-06-100
PRE
Th1/Th17 cytokine signatures correlate with Crohn’s disease activity in a 54‑week cohort of patients treated with adalimumab

Th1/Th17细胞因子特征与接受阿达木单抗治疗的克罗恩病患者54周队列中的疾病活动度相关

2026-05-290
OAAI
The TECCU-based telemonitoring platform for Inflammatory Bowel Disease is Cost-Effective: A Multicenter GETECCU Trial

基于TECCU的炎症性肠病远程监测平台具有成本效益:一项多中心GETECCU试验

2026-05-250
OAAI
Esophageal, gastric and duodenal Crohn’s disease in the biologic era: Results from a retrospective observational nationwide study of GETECCU
2026-01-310
PREAI
Clinical, Endoscopic, and Histological Characteristics of Severe Immune Checkpoint Inhibitor-Induced Colitis

重症免疫检查点抑制剂诱导性结肠炎的临床、内镜及组织学特征

2026-01-030
OAAI
Real-world effectiveness of vedolizumab in refractory pouchitis: a focus on biomarker changes during intravenous to subcutaneous transition (POUCHIVED study)

vedolizumab在难治性直肠炎中的真实世界有效性:重点关注从静脉给药转换为皮下给药期间生物标志物的变化(POUCHIVED研究)

2025-12-170
OAAI
Comparative Efficacy and Immunogenicity of Infliximab and Adalimumab in Crohn's Disease: A Prospective Cohort Study

英夫利昔单抗与阿达木单抗在克罗恩病中的比较疗效和免疫原性:一项前瞻性队列研究

2025-12-040
OAAI
Therapeutic management and risk of colectomy in patients with acute severe ulcerative colitis and previous exposure to anti-tumor necrosis factor drugs: a comparative study of GETECCU
2025-12-010
PRE
Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA Registry

老年患者术后克罗恩病的治疗管理及预后比较研究:ENEIDA登记研究数据

2025-12-010
OAAI
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA

生物制剂治疗炎症性肠病中剂量递增和递减的频率与效果:ENEIDA中的RAINBOW-IBD研究

2025-08-080
PRE
Natural history, immunological and genetic characteristics of preclinical inflammatory bowel disease (EARLY): study protocol for a prospective cohort study

自然病史、免疫学和遗传学特征,以及临床前期炎症性肠病(EARLY)的研究方案:一项前瞻性队列研究

2025-05-120
OA
Influence of Familial Inflammatory Bowel Disease History on the Use of Immunosuppressants, Biological Agents and Surgery in Patients with Pediatric-Onset of the Disease in the Era of Biological Therapies. Results from the ENEIDA Registry

有家族炎症性肠病史对生物制剂治疗时代儿童起病炎症性肠病患者免疫抑制剂、生物制剂使用及手术的影响。ENEIDA注册研究的结果。

2025-05-120
OA
Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU
2025-02-011
PRE
Cost of telemonitoring with the App TECCU in Inflammatory Bowel Disease compared to standard care in Spain: a multicenter clinical trial of GETECCU
2025-01-220
PRE
Time-trends in the management of postoperative Crohn's Disease and its impact on long-term surgical recurrence. Data from the ENEIDA registry
2025-01-220
PRE
Effectiveness and safety of upadacitinib in ulcerative colitis in clinical practice: results from the U-REAL-UC study from ENEIDA
2025-01-220
PRE